CN Patent

CN107383019B — 吡唑并[4,3-h]喹唑啉类化合物及其用途

Assigned to JIANGSU AIFAN BIOLOGICAL PHARMACEUTICAL Co Ltd · Expires 2019-10-15 · 7y expired

What this patent protects

本发明涉及一类如下通式I所示的吡唑并[4,3‑h]喹唑啉类衍生物及其用途，该类化合物具有抑制细胞周期蛋白依赖性酶家族(CDKs)中不同亚型例如CDK4/6的活性，为预防和治疗癌症、代谢与免疫疾病、心血管病以及神经性疾病提供新的手段。

USPTO Abstract

本发明涉及一类如下通式I所示的吡唑并[4,3‑h]喹唑啉类衍生物及其用途，该类化合物具有抑制细胞周期蛋白依赖性酶家族(CDKs)中不同亚型例如CDK4/6的活性，为预防和治疗癌症、代谢与免疫疾病、心血管病以及神经性疾病提供新的手段。

Drugs covered by this patent

trilaciclib-dihydrochloride (TRILACICLIB DIHYDROCHLORIDE)

Patent Metadata

Patent number: CN107383019B
Jurisdiction: CN
Classification: —
Expires: 2019-10-15
Drug substance claim: No
Drug product claim: No
Assignee: JIANGSU AIFAN BIOLOGICAL PHARMACEUTICAL Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.